En Es
Categories

Industry News

New AI Model Identifies Women Facing Future Risk of Breast Cancer

By Medimaging International staff writers
07 Jan 2020

IllustrationResearchers from the Karolinska Institute (Stockholm, Sweden) have developed a sophisticated type of artificial intelligence (AI) which can outperform existing models at predicting which women are at future risk of breast cancer.

Most existing breast cancer screening programs are based on mammography at similar time intervals -- typically, annually or every two years -- for all women. This "one size fits all" approach is not optimized for cancer detection on an individual level and may hamper the effectiveness of screening programs. High breast density, or a greater amount of glandular and connective tissue compared to fat, is considered a risk factor for cancer. While density may be incorporated into risk assessment, current prediction models may fail to fully take advantage of all the rich information found in mammograms. This information has the potential to identify women who would benefit from additional screening with MRI.

The Swedish researchers developed a risk model that relies on a deep neural network, a type of AI that can extract vast amounts of information from mammographic images. It offers inherent advantages over other methods such as visual assessment of mammographic density by the radiologist that may be unable to capture all risk-relevant information in the image. The new model was developed and trained on mammograms from cases diagnosed between 2008 and 2012 and then studied on more than 2,000 women ages 40 to 74 who had undergone mammography in the Karolinska University Hospital system. Of the 2,283 women in the study, 278 were later diagnosed with breast cancer.

The deep neural network showed a higher risk association for breast cancer as compared to the best mammographic density model. The false negative rate -- the rate at which women who were not categorized as high-risk were later diagnosed with breast cancer -- was lower for the deep neural network than for the best mammographic density model. The study findings support a future role for AI in breast cancer risk assessment. As an additional benefit, the AI approach can continually be improved with exposure to more high-quality data sets.

"The deep neural network overall was better than density-based models," said study lead author Karin Dembrower, M.D., breast radiologist and Ph.D. candidate from the Karolinska Institute in Stockholm, Sweden. "And it did not have the same bias as the density-based model. Its predictive accuracy was not negatively affected by more aggressive cancer subtypes."

Related Links:
Karolinska Institute



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

22 Jan 2020
Global Point of Care Testing (POCT) Market to Reach USD 46.7 Billion by 2024
 The global point of care testing (POCT) market is expected to surpass USD 37 billion by 2025, driven mainly by the migration of POCT from the hospital environment to a range of medical environments, including the workplace, home, disaster care and most recently, convenience clinics. POCT now appears to be headed for a bigger role in diagnosis and monitoring patient care. Additionally, growing awareness about early disease diagnosis and prevention has stimulated the demand for POCT for detecting cancer and infectious disease in the early stages. Moreover, the rising incidence of infectious diseases and chronic conditions, such as cardiovascular diseases and diabetes in the developing countries such as India and China, is stimulating the demand for POCT services.
Read More
16 Jan 2020
Radiomic Algorithm Predicts if Patient’s Cancer Can Return 10 Years After Treatment
 A new study by researchers at Penn Medicine (Philadelphia, PA, USA) has found that Magnetic Resonance Imaging (MRI) and an emerging field of medicine called radiomics — which uses algorithms to extract a large amount of features from medical images — could help to characterize the heterogeneity of cancer cells within a tumor and allow for a better understanding of the causes and progression of a person’s individual disease.
Read More
13 Jan 2020
PENTAX Medical Clears CE Mark for New AI-Assisted Polyp Detector
 PENTAX Medical (Tokyo, Japan) has cleared CE mark for DISCOVERY, its Artificial Intelligence (AI) assisted polyp detector designed to support endoscopists in finding potential polyps during a colorectal examination.
Read More
07 Jan 2020
Global EEG Devices Market to Reach USD 2.20 Billion in 2027
 The global EEG (Electroencephalography) devices market was valued at USD 1.12 billion in 2018 and is projected to grow at a CAGR of 7.8 % over the forecast period 2019-2027 to reach USD 2.20 billion in 2027, driven mainly by the increasing prevalence of sleep disorders.

Read More
06 Jan 2020
Google AI System Beats Doctors in Detecting Breast Cancer
 A team of researchers from Google Health (Palo Alto, CA, USA) have developed an artificial intelligence (AI) model which can spot breast cancer in de-identified screening mammograms (where identifiable information has been removed) with greater accuracy, fewer false positives, and fewer false negatives than experts. This can find future applications wherein the model could support radiologists performing breast cancer screenings.
Read More
03 Jan 2020
Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler
 Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More
03 Jan 2020
Global Hematology Diagnostic Devices and Equipment Market to Reach USD 2.35 Billion by 2022
 The global hematology diagnostic devices and equipment market was valued at about USD 1.9 billion in 2018 and is projected to grow to at a CAGR of 5.5% to USD 2.35 billion in 2022. The market growth is driven mainly by an increase in the use of hematology diagnostic devices due to the rising prevalence of blood disorders which affect millions of people each year across the world, irrespective of age, race, and sex.
Read More
03 Jan 2020
Global Immunochemistry Diagnostic Devices and Equipment Market to Reach USD 19.24 Billion by 2022
 The global immunochemistry diagnostic devices and equipment market was valued at about USD 16.7 billion in 2018 and is projected to grow at a CAGR of 3.6% to USD 19.24 billion in 2022. The market growth will be driven by an increase in the incidence of target diseases, such as viral infections, cardiovascular diseases, cancer or hormonal disorders worldwide, mainly due to poor lifestyle choices.
Read More
02 Jan 2020
AI Outperforms Radiologists in Detecting Tiny Brain Hemorrhages on CT Scans
 Scientists at UC San Francisco (San Francisco, CA, USA) and UC Berkeley (Berkeley, CA, USA) have developed an algorithm that performed better than two out of four expert radiologists in finding tiny brain hemorrhages in head scans. The algorithm could help doctors treat patients with traumatic brain injuries (TBI), strokes and aneurysms.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions